Biotech stocks were among 2017’s best performers, until news broke in October that congressional Republicans ditched efforts to repeal and replace Obamacare. The iShares Nasdaq Biotechnology Index Fund ETF (Nasdaq: IBB) slid 11.5% that month, which was well into correction territory.
In fact, the best biotech stock we’re bringing readers today could bring gains of over 110% in 2018 alone…
The warnings against buying biotech stocks in 2018 are wrong. According to Money Morning Director of Technology & Venture Capital Research Michael A. Robinson, biotech stocks are extremely undervalued now, and biotech investing is the best way to double your money in 2018.
Before we get to Robinson’s top biotech stock, here’s why we’re so bullish on biotech in 2018…
The Best Biotech Stocks Are Absolute Bargains Right Now
As a nation, we are not getting any younger. And that means the need to combat the effects of aging and a wide range of diseases can only grow.
In fact, the Heritage Foundation forecasts that by 2050, the percentage of Americans older than 65 will grow from its current 14% to over 20% of the population. And the percentage of Americans older than 85 will more than double, to just over 4%.
In the United States, the biotech sector is already worth $162.6 billion. That number will balloon thanks to our aging demographics.
But that is not the only catalyst for biotech sector growth. Merger activity is robust. In 2017, we saw deals valued as high as $11 billion. Baker McKenzie expects the biotech M&A market to grow as much as 50% in 2018 from last year.
And finally, politics have tilted in biotech’s favor. Regulations are down as the shroud over drug price policy lifts. Approvals for new treatments should happen faster.
After last year’s correction, now seems to be a perfect time to take advantage of this sector’s coming growth spurt.
That’s why we’re recommending this top biotech stock in 2018. According to Robinson, it could double your money in the next 11 months…
Here’s the Best Biotech Stock to Buy in 2018
Robinson’s top biotech stock is a comeback story, as it currently trades at a big discount from the S&P 500 based on forward earnings multiples.
Shire Plc. (Nasdaq: SHPG) may be the least-understood Big Pharma firm out there right now.
Analysts expect the FDA to approve competitor Roche’s ACE 910 hemophilia treatment next month. Yet, the market prices Shire shares as if its entire share of this niche is going to evaporate completely. That would be a loss of 20% of the firm’s revenue.
But that’s not going to happen. Sure, some share will go to the competition, but Shire’s FEIBA drug still enjoys a wide appeal in the medical community.
Not only that, but Shire still has a robust drug pipeline, with 33 drugs in clinical trials, half of which are in final phase 3 trials. That’s pretty good for a stock that trades at about $145 per share – 25.5% off its 2017 high. That’s about nine times forward earnings, or a 53% discount, from the S&P 500.
If it just traded at the market’s forward multiple, it would reach about $311.51, based on 2018 estimated earnings. That’s a profit of 115%.
Source: Money Morning